1. Scrip
  2. >>Business
  3. >>Start-Ups & SMEs
  4. >>Emerging Company Profiles

Kinaset Advances Inhaled Pan-JAK Inhibitor For Broad Use In Severe Asthma

 
• By Ayisha Sharma

Emerging Company Profile: The US biotech acquired its sole asset from CDMO Vectura in 2020 and is now gearing up for a Phase II proof-of-concept trial in severe asthma to help address the unmet need in non-eosinophilic patients.  

Emerging Company Profile: Kinaset Therapeutics
Severe Asthma Patients Can Experience Exacerbations • Source: Shutterstock
Key Takeaways:

  • Kinaset’s lead candidate, KN-002, is a pan-JAK inhibitor for severe asthma and COPD.

  • KN-002 will enter three-armed Phase II proof-of-concept trial later this year.

  • The inhaled drug could provide a more convenient option for some non-eosinophilic patients.

Kinaset Therapeutics, Inc

The firm’s roots can be traced back to the 2019 transition of former drug development firm Vectura Group plc into a CDMO. During the shift, Vectura chose to out-license its entire pipeline, including an inhaled pan-JAK inhibitor asset

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Emerging Company Profiles

Immusoft Goes For Cell Therapy Plan ‘B’

 
• By Alaric DeArment

Emerging Company Profile: CEO Sean Ainsworth spoke with Scrip about how the company is developing B-cell therapies to treat a range of diseases, starting with MPS I.

Sanofi-Backed Resalis Brings MicroRNA To Obesity

 
• By Elizabeth Cairns

Emerging Company Profile: Resalis will soon start human trials of an oligonucleotide targeting a microRNA that is overexpressed in obese mice, but much remains to be proven in humans.

Volastra Aims To Terminate Cancer Relying On Chromosomal Instability

 
• By Jessica Merrill

Emerging Company Profile: Volastra is testing two KIF18A inhibitors in early clinical trials in ovarian cancer, backed by investors like Polaris Partners and ARCH Ventures.

Seraxis Takes Its Islet Cell Tech Into The Clinic

 
• By Elizabeth Cairns

Emerging Company Profile: The Maryland-based biotech is working on a functional cure for type 1 diabetes that is similar to Vertex’s VX-880 – but with some key differences.

More from Start-Ups & SMEs